Preventing renal dysfunction in patients with hypertension: clinical implications from the early AASK Trial results.

Journal Article (Journal Article;Review)

Strategies to delay progression of established renal disease have primarily been directed at examining the class of antihypertensive therapy and/or the level of blood pressure control. In diabetic renal disease many trials have noted a protective role of ACE inhibitor-based therapy over non-ACE inhibitor-based therapy. This paper reviews recent clinical trials evaluating hypertension-related kidney disease including the interim results of the African-American Study of Kidney Diseases and Hypertension (AASK) Study, to date the largest prospective study of African-American patients with kidney disease due to hypertension. This trial reports a renoprotective effect of ACE inhibitor-based therapy over calcium-channel antagonist- based therapy. The renoprotective effect of ACE inhibitor-based therapy may, in part, be due to their antiproteinuric effect independent of blood pressure lowering.

Full Text

Duke Authors

Cited Authors

  • Lea, JP; Brown, DT; Lipkowitz, M; Middleton, J; Norris, K; AASK Study Group,

Published Date

  • 2003

Published In

Volume / Issue

  • 3 / 3

Start / End Page

  • 193 - 200

PubMed ID

  • 14727931

Pubmed Central ID

  • 14727931

International Standard Serial Number (ISSN)

  • 1175-3277

Digital Object Identifier (DOI)

  • 10.2165/00129784-200303030-00005

Language

  • eng

Conference Location

  • New Zealand